Verseon Corp said the US Patent and Trademark Office has granted it US Patents No. 9,533,967 and 9,533,970, which cover various aspects of multiple families of compounds.
Verseon had previously obtained patent protection in China, New Zealand, Israel, and Australia related to the subject matter of US Patent 9,533,967.
Among other aspects, the patents demonstrate the novelty and nonobviousness of compounds related to Verseon's anticoagulant program.
In preclinical studies, the Company's oral direct thrombin inhibitors have demonstrated efficacy comparable to current anticoagulants along with reduced bleeding risk and are expected to enter clinical trials in 2017.
"The newly issued patents are an important milestone in our ongoing effort to strengthen the intellectual property protection for our drug programs in key markets.
"We expect to receive further patents in the near future," said David Kita, co-founder and Vice President of Research and Development at Verseon. "Our anticoagulant candidates have the potential to change the standard of care for millions of patients with thrombosis-related disorders."